IRRITATION STUDIES

Primary Eye Irritation on Rabbits
Instillation of pyrimidifen technical (about 46 mg/eye) into the eyes of one male and five female New Zealand White rabbits caused slight irritant effects of transient conjunctival inflammation, being, however, reversible within 3 days. Formulation (4%-SC, 0.1 ml/eye, six male New Zealand White rabbits) caused slight conjunctival irritation. Full recovery was observed within 2 days. Furthermore, there were no positive response, corneal damage or iridial inflammation in 1000-fold dilution of 4%-SC formulation (0.1 ml/eye, one male and five female New Zealand White rabbits) which is a practical dosage. It's instillation elicited temporary mild conjunctival irritation only.
(Huntingdon Research Centre Ltd., 1991 and 1993)
Primary Dermal Irritation on Rabbits
Pyrimidifen technical (0.5 g) or it's formulation (4%-SC, 0.5ml) were applied to the intact skin of New Zealand White rabbits (technical; three males and three females, formulation; six males). Both of them showed no response to treatment in any animal throughout the observed period. There was no dermal irritation. (Huntingdon Research Centre Ltd., 1991 and 1992) 
Dermal Sensitization Study on Guinea Pigs
Three induction applications of pyrimidifen technical (0.5 ml, 65% w/w in acetone) or it's formulation (0.5 ml of 4%-SC) were made once a week for 3 weeks. Ten female Dunkin/Hartley guinea pigs were challenged using pyrimidifen technical (0.5 ml, 65% w/w in acetone) or it's formulation (0.5 ml of 4%-SC and 50% v/v in distilled water) after the 3rd induction application respectively. Their potential to induce delayed contact hyper-sensitivity was evaluated according to Buehler test. Both pyrimidifen technical and it's formulation (4%-SC) showed no evidence of dermal sensitization potential.
(Huntingdon Research Centre Ltd., 1991 and 1992)
SUB-CHRONIC TOXICITY STUDIES 1. Thirteen-Week Feeding Study on Rats
Groups of 12 male and 12 female Fischer (F344/ DuCrj) rats were fed diet containing 0, 10, 30, 100 and 150 ppm of pyrimidifen for 13 weeks. Treatments in 100 ppm or higher male and female caused the depression or the depressing tendency of bodyweight gain, reduced food consumption, some changes in hematology and blood biochemistry and increased kidney weight. Liver weight was increased in 10 ppm or higher female and 100 ppm or higher male. Therefore, the NOEL for this study was considered to be 30 ppm (1.794 mg/kg/day) in male and less than l0 ppm (0.693 mg/kg/day) in female.
(The Institute of Environmental Toxicology, 1990)
Thirteen-Week Feeding Study on Mice
Groups of 12 male and 12 female ICR (Crj: CD-1) mice were fed diet containing 0, 10, 30, 100 and 300 ppm of pyrimidifen for 13 weeks.
Increased liver and kidney weights were noted at 100 ppm or higher females. Centrilobular hepatocellular swelling of the liver was observed at 300 ppm of male and female. A decreasing tendency of food consumption and slight anemia were also observed at 300 ppm female. In males in the 100 ppm group and in females and males in 30 and 10 ppm groups, there were no treatment-related changes in the examinations.
Therefore, the NOEL for this study was considered to be 100 ppm (13.4 mg/kg/day) in male and 30 ppm (5.33 mg/kg/day) in female.
Thirteen-Week Oral Toxicity Study on Dogs
Groups of 4 male and 4 female beagle dogs were administered orally via gelatin capsule at dose levels of 0, 0.15, 0.5, 1.5 and 4.5 mg/kg/day of pyrimidifen for 13 weeks. Increased frequency of vomiting and liquid faeces were noted at 0.5 mg/kg/day or higher. Reduced bodyweight gain, reduced food intake and occasional incidence of salivation were also noted at 4.5 mg/kg/day. The NOAEL for this study was considered to be 0.15 mg/kg/day in male and female.
(Huntingdon Research Centre Ltd., 1992)
CHRONIC TOXICITY AND ONCOGENICITY STUDIES 1. Combined Chronic Toxicity and Oncogenicity Study on Rats
Groups of 50 male and 50 female Fischer (F344/ DuCrj) rats were fed diet containing 0, 3, 10, 30 and 100 ppm of pyrimidifen for 104 weeks.
Treatments in 30 ppm or higher males and females caused the depression of bodyweight gain and reduced food consumption. The decrease of hemoglobin and the increase of relative liver weight were observed in 30 ppm or higher females. In 100 ppm females, the dark-coloured kidneys were observed and kidney weight and brown pigment deposition (lipofuscin) in the tubular epithelium of the kidneys was increased. On the other hand, increased pheochromocytoma (benign) in the adrenal was noted in 100 ppm males. In addition, there was no significant difference between the total number of neoplastic lesions (especially malignant tumors) nor the number of animals having the neoplastic lesion of the treated groups and those of the control group. In 10 ppm and 3 ppm groups, neither male nor female showed findings attributable to the treatment in any examinations.
Therefore, the NOEL for this study was considered to be 10 ppm in both male and female (male: 0.338 mg/kg/ day, female: 0.427 mg/kg/day) and no apparent oncogenicity was indicated.
(The Institute of Environmental Toxicology, 1993)
Oncogenicity Study on Mice
Groups of 50 male and 50 female ICR (Crj: CD-1) mice were fed diet containing 0, 10, 30, 100 and 300 ppm of pyrimidifen for 86 weeks.
In 100 ppm or higher males and females, decrease or decreasing tendency of bodyweight gain was observed. Males and females in the 300 ppm group showed lower food consumption, lower food efficiency and so on. In 30 and 10 ppm groups, there were no toxic effects related to the test substance. In addition, there were no significant increases in the incidence of neoplastic lesions in any treated group. Therefore, the NOEL for this study was considered to be 30 ppm in both male and female (male: 2.839 mg/kg/day, female: 2.638 mg/kg/day) and no oncogenicity was indicated.
Chronic Toxicity Study on Dogs
Groups of 4 male and 4 female beagle dogs were administered orally via gelatin capsule at dose levels of 0, 0.15, 0.75 and 3.75 mg/kg/day of pyrimidifen for 52 weeks.
In 0.75 mg/kg/day or higher male and female, clinical signs of liquid faeces, vomiting and salivation prior to dose administration were noted throughout the treatment period. In 0.15 mg/kg/day, the incidence of liquid faeces was slightly greater than that of control but individual incidence was almost same as that of control. There was no difference between the treatment groups and the control one in any other investigations.
Therefore, the NOAEL for this study was considered to be 0.15 mg/kg/day in male and female.
(Huntingdon Research Centre Ltd., 1993)
Chronic Toxicity Study on Dogs for 26 Weeks (Additional Study)
Groups of 4 male and 4 female beagle dogs were administered orally via gelatin capsule at dose levels of 0, 0 (lactose), 0.l0, 0.12, 0.15 and 0.75 mg/kg/day of pyrimidifen for 26 weeks to ensure a NOEL in beagle dogs. Only in 0.75 mg/kg/day group, the incidence of liquid faeces and vomiting were increased. In any other treated groups, there were no changes related to the test substance. According to the results in both the above mentioned chronic toxicity study on dogs and this study, 0.15 mg/kg/day can be considered to be the NOEL.
(Huntingdon Research Centre Ltd., 1 993)
REPRODUCTION STUDY Groups of 32 male and 32 female Crl: CD (SD) rats were fed diet containing 0, 10, 30 and 100 ppm of pyrimidifen throughout two generations. In 100 ppm parental animals, reduced food consumption and reduced bodyweight gain, increased liver weight and some changes in histopathological examination were noted. For litters, reduction of bodyweight gain and differences of organ weights were noted and there was no influence of fertility in any group. At neither 10 or 30 ppm, there were no apparent treatment-related effects and changes. Therefore, the NOEL for parent animals was considered to be 30 ppm (male: 2.2-2.5 mg/kg/day, female: 2.5-2.7 mg/kg/day) and that for reproduction to be 100 ppm (male: 7.6-8.4 mg/kg/day, female: 8.3-9.5 mg/kg/day) (Huntingdon Research Centre Ltd., 1992)
TERATOGENICITY STUDIES l. Teratogenicity Study on Rats
Pyrimidifen was administered by oral gavage at dose levels of 0, l, 5 and 25 mg/kg/day to groups of 24 pregnant Crl: CD (SD) rats for 10 days. In 25 mg/kg/ day parental females, reduced bodyweight gain and reduced food consumption were noted during the early phase of the treatment. For the developing foetus of this dose level, their mean weight was slightly reduced and some retardation of ossification and an increase in the incidence of foetuses with 14 th rib were noted. Administration of this substance at 1 or 5 mg/kg/day had no discernible effects on either the mother or the developing foetus.
